FMP
TransCode Therapeutics, Inc.
RNAZ
NASDAQ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
0.404 USD
0.0054 (1.34%)
Operating Data
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue
-
-
-
-
-
-
-
-
-
-
Revenue %
-
-
-
-
-
-
-
-
-
Ebitda
-
-
-6.11M
-17.47M
-17.97M
-
-
-
-
-
Ebitda %
100
100
100
100
100
100
100
100
100
Ebit
-456.87k
-726.6k
-6.15M
-17.56M
-18.49M
-
-
-
-
-
Ebit %
100
100
100
100
100
100
100
100
100
Depreciation
456.87k
726.6k
42.47k
98.61k
516.75k
-
-
-
-
-
Depreciation %
100
100
100
100
100
100
100
100
100
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
